GRL-142
GRL-142 is a potent HIV-1 protease inhibitor capable of crossing the blood-brain barrier. GRL-142 exhibits extremely high inhibitory activity against both wild-type and multidrug-resistant strains (IC50=0.0094 nM). GRL-142 acts synergistically with the P2/P2' segments via a unique scaffold binding mechanism, utilizes fluorine-mediated stable interactions to maintain its bioactive conformation, adapts to p51 HIV-1 protease mutants, and maintains the flap-closed state by directly acting on the flap tip residues. GRL-142 disrupts the flap-water hydrogen bond network of wild-type protease, thereby effectively blocking viral replication. GRL-142 can be used to study HIV-1 infection and the associated neurocognitive disorder (HAND).
For research use only. We do not sell to patients.
- Formula: C34H40F2N4O7S2
- Molecular Weight:718.83
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
HIV-1 |
GRL-142 exhibits ultra-potent inhibitory activity against wild-type HIV-1 (Ki=14 pM), and maintains high activity against most drug-resistant HIV-1 strains, but shows a significant reduction in activity against highly drug-resistant p51 strains (with a maximum reduction of 436-fold)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Molecular Weight 718.83
-
Formula C34H40F2N4O7S2
-
SMILES
[H][C@]1(C2CO[C@@]3(OCC4(C23)CC41)[H])OC(N[C@H]([C@@H](CN(S(=O)(C5=CC6=C(N=C(S6)NC7CC7)C=C5)=O)CC(C)C)O)CC8=CC(F)=CC(F)=C8)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- GRL-142
- GRL142
- GRL 142
- HIV
- HIV Protease
- flap-tip residue
- flap-water hydrogen bonding networks
- p51 HIV-1 protease variant
- drug-resistant HIV-1 strains
- blood-brain barrier
- HIV-associated neurocognitive disorders
- S2/S2' subsites
- multidrug-resistant HIV-1 protease
- HIV-1 infection
- wild-type HIV-1 protease
- Inhibitor
- inhibitor
- inhibit